New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe ... Read More
Eli Lilly receives FDA response letter for eczema treatment lebrikizumab
Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe ... Read More
Lilly to acquire US dermatology drug company Dermira for $1.1bn
Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 ... Read More